Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.

Melanoma research - 1 Aug 2022

Wolfe Zachary, Friedland Julie C, Ginn Sarah, Blackham Aaron, Demberger Lauren, Horton Morgan, McIntosh Alyson, Sheikh Hina, Box Jessica, Knoerzer Deborah, Federowicz Bryan, Stuhlmiller Timothy J, Shapiro Mark, Nair Suresh

Abstract excerpt

Melanoma is characterized by oncogenic mutations in pathways regulating cell growth, proliferation, and metabolism. Greater than 80% of primary melanoma cases harbor aberrant activation of the mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase (MEK/ERK) pathway, with oncogenic mutations in BRAF, most notably BRAF V600E, being the most common. Significant progress has been made in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Mitogen-Activated Protein Kinase Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Pyrroles

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35551160
DOI: 10.1097/CMR.0000000000000830
PMCID: PMC9245552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.PMID 35551160Read ↗

BRAF L597K mutation: an opportunity to treat.Semantic proximity Read ↗

Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

Management of a patient with advanced BRAF-mutant melanoma.Semantic proximity Read ↗

Major Clinical Response to a BRAF Inhibitor in a Patient With a <i>BRAF</i> L597R–Mutated MelanomaSemantic proximity Read ↗

A review of binimetinib for the treatment of mutant cutaneous melanoma.Semantic proximity Read ↗

Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.Semantic proximity Read ↗

BRAFV600E-mutant melanoma presenting with cardiac involvement.Semantic proximity Read ↗

[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].Semantic proximity Read ↗

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.